Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 16OTHER 14NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Small Cell Lung Carcinoma 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1Advanced Rare Tumours 1

Interventions

Cyclophosphamide 39Docetaxel 30Tamoxifen 29Paclitaxel 27Doxorubicin 26Trastuzumab 20Radiotherapy 18Epirubicin 16Letrozole 13exemestane 11Fluorouracil 11Anastrozole 11Capecitabine 10Bevacizumab 10Immunohistochemistry 9Filgrastim 9Fulvestrant 8Methotrexate 7Gene Expression Profiling 7palbociclib 6Zoledronic Acid 6Microarray Analysis 6Lapatinib 6Goserelin 6Chemotherapy, Adjuvant 6Amplified Fragment Length Polymorphism Analysis 6Vinorelbine 5Triptorelin Pamoate 5Carboplatin 5Absorptiometry, Photon 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Breast Neoplasms × Sunitinib × Clear all
NCT00482755 2024-02-12

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Canadian Cancer Trials Group

Phase 2 Completed
4 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡